|
注册号: Registration number: |
ChiCTR2600116518 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-12 11:13:19 |
|
注册时间: Date of Registration: |
2026-01-12 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
急性胰腺炎感染风险预警 |
|
Public title: |
Risk warning of secondary infection in acute pancreatitis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于色氨酸代谢产物谱的急性胰腺炎继发性感染风险的Nomogram预警模型的建立 |
|
Scientific title: |
A nomogram model base on Tryptophan Metabolite Profile in patients with Acute Pancreatitis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
于倩 |
研究负责人: |
于倩 |
|
Applicant: |
Qian Yu |
Study leader: |
Qian Yu |
|
申请注册联系人电话: Applicant telephone: |
+86 580 204 5223 |
研究负责人电话:
Study leader's |
+86 580 204 5223 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
35942726@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
35942726@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江省舟山市定海区新桥路355号 |
研究负责人通讯地址: |
浙江省舟山市定海区新桥路355号 |
|
Applicant address: |
No. 355, Xinqiao Road, Dinghai District, Zhoushan City, Zhejiang province |
Study leader's address: |
No. 355, Xinqiao Road, Dinghai District, Zhoushan City, Zhejiang province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
舟山市中医院 |
||
|
Applicant's institution: |
Zhoushan Cuty Triditional Hospital |
||
|
研究负责人所在单位: |
舟山市中医院 |
||
|
Affiliation of the Leader: |
Zhoushan Hospital of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2025)伦审第(69)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
舟山市中医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Zhoushan Hospital of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-12-30 00:00:00 | ||
|
伦理委员会联系人: |
谢琼 |
||
|
Contact Name of the ethic committee: |
Xie Qiong |
||
|
伦理委员会联系地址: |
浙江省舟山市定海区新桥路355号 |
||
|
Contact Address of the ethic committee: |
No. 355, Xinqiao Road, Dinghai District, Zhoushan City, Zhejiang province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 580 2619032 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
364745212@qq.com |
|
研究实施负责(组长)单位: |
舟山市中医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhoushan Hospital of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省舟山市定海区新桥路355号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 355, Xinqiao Road, Dinghai District, Zhoushan City, Zhejiang province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
浙江省医药卫生科技计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Zhejiang Province Medical and Health General Project |
||||||||||||||||||||||
|
研究疾病: |
急性胰腺炎,伴或不伴胰腺实质变化和(或)器官衰竭 |
||||||||||||||||||||||
|
Target disease: |
Acute pancreatitis, with or without changes in the pancreatic parenchyma and/or organ failure |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
通过临床指征和基于色氨酸代谢产物谱的实验室指征,构建列线图预测模型,并评估模型对AP患者继发性感染发生率的预测价值。 |
||||||||||||||||||||||
|
Objectives of Study: |
By utilizing clinical indicators and laboratory indicators based on tryptophan metabolite profiles, a nomogram prediction model was constructed and its predictive value for the incidence of secondary infections in patients with acute pancreatitis (AP) was evaluated. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
肿瘤患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Cancer patien. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2028-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-01-15 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
no share |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表,电子数据表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
data collection,electronic data capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |